Janux Therapeutics EBITDA 2020-2024 | JANX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Janux Therapeutics ebitda from 2020 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Janux Therapeutics ebitda from 2020 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$146.3B
Gilead Sciences (GILD)	$114.5B
Bristol Myers Squibb (BMY)	$114.2B
Vertex Pharmaceuticals (VRTX)	$108.7B
CSL (CSLLY)	$83.4B
Regeneron Pharmaceuticals (REGN)	$74.9B
GSK (GSK)	$69.3B
Argenex SE (ARGX)	$38.7B
Alnylam Pharmaceuticals (ALNY)	$31.8B
BioNTech SE (BNTX)	$26.8B
Illumina (ILMN)	$21.7B
BeiGene (ONC)	$20.5B
Biogen (BIIB)	$20.5B
Incyte (INCY)	$13.9B
Genmab (GMAB)	$13.8B
Genmab (GNMSF)	$13.7B
Intra-Cellular Therapies (ITCI)	$13.4B
Moderna (MRNA)	$13.1B
Insmed (INSM)	$13B
Bio-Techne Corp (TECH)	$12B
BioMarin Pharmaceutical (BMRN)	$11.7B
Sarepta Therapeutics (SRPT)	$11.3B
Vaxcyte (PCVX)	$10.6B
QIAGEN (QGEN)	$10.5B
Exelixis (EXEL)	$10.3B
Swedish Orphan Biovitrum (BIOVF)	$10.1B
Exact Sciences (EXAS)	$9.6B
Bio-Rad Laboratories (BIO.B)	$9.5B
Repligen (RGEN)	$9B
Roivant Sciences (ROIV)	$8.1B